Aislinn Antrim, Associate Editorial Director

Patients with triple-negative breast cancer treated with veliparib had statistically significantly longer survival than those given placebo.

In a clinical trial program, 92% of health care providers, patients, and caregivers were able to successfully administer tezepelumab-ekko both in the clinic and at home for severe asthma.

Belimumab was the first and only approved biologic for active systemic lupus erythematosus and lupus nephritis in more than 50 years, including for pediatric patients.

Study findings mark the first evidence of improved health-related quality of life scores following treatment with an investigational microbiome agent in patients with recurrent Clostridioides difficile.

Peripheral artery disease is more common in Black patients than any other racial or ethnic group, but its potential association with negative social determinants of health is not known.

IQVIA report states that appropriate reimbursement for all health care professionals who provide immunization services would encourage their ongoing provision of vaccines.

CVS and Walgreens have both recently announced that they are seeking FDA certification to use the mail to distribute mifepristone, the first pill used in a 2-drug abortion.

Researchers found a 27% heightened risk of cardiovascular disease for individuals with celiac disease compared with those who didn’t have the condition.

The trial is the first randomized phase 3 study evaluating the efficacy and safety of ciltacabtagene autoleucel patients with relapsed and lenalidomide-refractory multiple myeloma.

The mRNA-1345 vaccine candidate was previously granted Fast Track designation by the FDA in August 2021.

The agency also denied 3 citizen petitions asking for CBD products to be marketed as dietary supplements.

Lisocabtagene maraleucel is a CD19-directed CAR T-cell therapy with a 4-1BB costimulatory domain, which enhances the expansion and persistence of the CAR T cells.

The updated label now includes patients with cold agglutinin disease with or without a history of transfusions.

The test, called VirSNiP SARS-CoV-2 Spike F486P, is for research use only and specifically targets the unique mutation F486P found within the XBB.1.5 Omicron sub-variant.

The moves come after other efforts to improve staff shortages, including higher wages, lunch breaks, and signing bonuses.

Increasing efforts have focused on treating COVID-19 among patients in rural areas, who can take advantage of traditional medicines.

Findings suggest cancer may have overtaken cardiovascular disease as a leading cause of death in individuals with type 2 diabetes.

Relatively higher suicide risks were observed for cancer types with a poor prognosis and high symptom burden in the first 2 years after diagnosis.

Chronochemotherapy aims to time drug delivery when the body is the least vulnerable to harmful effects, while the cancer cells are the most vulnerable.

In younger children, emotional maltreatment led primarily to behavioral problems, whereas in older children it was more likely to lead to depression and anxiety disorders.

Pharmacist involvement in identifying causes, therapy approaches is essential, as BCC can result from prior radiation therapy.

Based on study findings, Moderna plans to submit for regulatory approval in the first half of 2023 for mRNA-1345, a novel vaccine for respiratory syncytial virus.

Specific data and results for pembrolizumab in patients with advanced or unresectable biliary tract cancer will be presented at an upcoming medical meeting and will be submitted to regulatory authorities.

Study highlights the impact of individual expectations for positive and negative outcomes.

The investigators observed a 96.8% S. aureus reduction in stool and a 65.4% reduction in the nose among patients who received the probiotic.

Surgical embolectomy and venoarterial extracorporeal membrane oxygenation demonstrate favorable safety and efficacy profiles.

In a phase 3 trial, empagliflozin significantly reduced the risk of kidney disease progression or cardiovascular death in adults with chronic kidney disease by 28% compared with placebo.

New findings reveal the previously misunderstood mechanism by which PCSK9 degrades the low-density lipoprotein receptor.

In patients with HER2-expressing metastatic gastroesophageal adenocarcinoma administered zanidatamab, the median duration of response was 20.4 months, with a median progression-free survival of 12.5 months.

The Amazon Pharmacy service will also have pharmacists on-call 24/7, according to the announcement.